Celea Therapeutics
VS
Sanofi

Biotech comparison — funding, valuation, and investors, sourced from Value Add Pulse coverage.

CT
Celea Therapeutics

Clinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.

4 Pulse stories
S
Sanofi

Sanofi is a global biopharmaceutical company developing and manufacturing medicines and vaccines across specialty care, immunology, oncology, and rare diseases.

2 Pulse stories
Total Raised
$180M
Celea TherapeuticsSanofi
Last ValuationNot disclosed
Biotech
Sector
Biotech
2025
Founded
1973
Boston, MA
HQ
Paris, France
Private
Status
Public (SNY)
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Sanofi investors
No investors on record.

Data from Value Add Pulse coverage and company research — see the full threads for Celea Therapeutics and Sanofi.